Current and Potential Therapies Targeting Inflammation in NASH

被引：31

作者：

Albhaisi, Somaya ^{[1
]}

Noureddin, Mazen ^{[2
]}

机构：

[1] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA

[2] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Karsh Div Gastroenterol & Hepatol, Los Angeles, CA 90048 USA

来源：

FRONTIERS IN ENDOCRINOLOGY | 2021年 / 12卷

关键词：

non-alcoholic steatohepatitis; inflammation; treatment; macrophages; lymphocytes; cytokines; hepatocellular injury; oxidative stress; FATTY LIVER-DISEASE; NONALCOHOLIC STEATOHEPATITIS PATIENTS; FARNESOID X RECEPTOR; EXTRACELLULAR VESICLES; S-ADENOSYLMETHIONINE; DIAGNOSTIC-ACCURACY; HEPATIC STEATOSIS; NATURAL-HISTORY; VITAMIN-D; FIBROSIS;

D O I：

10.3389/fendo.2021.767314

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease (NAFLD). It is characterized by hepatic steatosis, inflammation, hepatocellular injury, and fibrosis. Inflammation plays a key role in the progression of NASH and can be provoked by intrahepatic (e.g., lipotoxicity, immune responses, oxidative stress and cell death) and extrahepatic sources (adipose tissue or gut). The identification of triggers of inflammation is central to understanding the mechanisms in NASH development and progression and in designing targeted therapies that can halt or reverse the disease. In this review, we summarize the current and potential therapies targeting inflammation in NASH.

引用

收藏

页数：8

相关论文

共 50 条

[21] Therapeutic Effect of Crocin on the NASH Model by Targeting the Fas Receptor Signaling Pathway [J].

Mard, Seyyed Ali ;

Savari, Feryal ;

Rezaie, Anahita ;

Khosravi, Maryam .

TURKISH JOURNAL OF GASTROENTEROLOGY, 2022, 33 (06) :505-514

[22] Nephropathic Cystinosis: Pathogenic Roles of Inflammation and Potential for New Therapies [J].

Elmonem, Mohamed A. ;

Veys, Koenraad R. P. ;

Prencipe, Giusi .

CELLS, 2022, 11 (02)

[23] The contribution of sterile inflammation to the fatty liver disease and the potential therapies [J].

Shaker, Mohamed E. .

BIOMEDICINE & PHARMACOTHERAPY, 2022, 148

[24] Nonalcoholic fatty liver disease: Current and potential therapies [J].

Ibrahim, Mohamed Abdellah ;

Kelleni, Mina ;

Geddawy, Ayman .

LIFE SCIENCES, 2013, 92 (02) :114-118

[25] Targeting Lung Inflammation: Novel Therapies for the Treatment of COPD [J].

Yao, Hongwei ;

de Boer, Willem I. ;

Rahman, Irfan .

CURRENT RESPIRATORY MEDICINE REVIEWS, 2008, 4 (01) :57-68

[26] Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH [J].

Maeda, Hitoshi ;

Ishima, Yu ;

Saruwatari, Junji ;

Mizuta, Yuki ;

Minayoshi, Yuki ;

Ichimizu, Shota ;

Yanagisawa, Hiroki ;

Nagasaki, Taisei ;

Yasuda, Kengo ;

Oshiro, Shun ;

Taura, Manabu ;

McConnell, Matthew J. ;

Oniki, Kentaro ;

Sonoda, Kayoko ;

Wakayama, Tomohiko ;

Kinoshita, Manabu ;

Shuto, Tsuyoshi ;

Kai, Hirofumi ;

Tanaka, Motohiko ;

Sasaki, Yutaka ;

Iwakiri, Yasuko ;

Otagiri, Masaki ;

Watanabe, Hiroshi ;

Maruyama, Toru .

JOURNAL OF CONTROLLED RELEASE, 2022, 341 :457-474

[27] Emerging therapies for NASH - the future is now [J].

Geier, Andreas ;

Rau, Monika .

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (05) :467-469

[28] Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH [J].

Fraser, David A. ;

Harrison, Stephen A. ;

Schuppan, Detlef .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (12) :1269-1278

[29] Inflammation:A novel target of current therapies for hepatic encephalopathy in liver cirrhosis [J].

Ming Luo ;

Jian-Yang Guo ;

Wu-Kui Cao .

World Journal of Gastroenterology, 2015, (41) :11815-11824

[30] Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis [J].

Luo, Ming ;

Guo, Jian-Yang ;

Cao, Wu-Kui .

WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (41) :11815-11824

← 1 2 3 4 5 →